Pamela Esposito, Director of Kymera Therapeutics KYMR, has filed 0 purchases and 23 sales on the open market. Over the past 12 months that comes to a net sale of $3.1M. The latest trade was on 06/24.

PE

PE

Pamela Esposito

Director

Company

Kymera Therapeutics KYMR

First filing

23/04/04

Trades

67 trades

Buys / sales

0 / 23

12-month net buying

−$3.1M

Last trade

06/24

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Kymera TherapeuticsKYMR	Open-market sale10b5-1 plan	03/20	03/20	2,500 sh3 trades	$79.15avg.	$197,869	−100.0%
Kymera TherapeuticsKYMR	Open-market sale10b5-1 plan	02/20	02/20	2,500 sh2 trades	$87.31avg.	$218,274	−100.0%
Kymera TherapeuticsKYMR	Open-market sale10b5-1 plan	01/20	01/20	5,500 sh3 trades	$67.91avg.	$373,527	−100.0%
Kymera TherapeuticsKYMR	Open-market sale10b5-1 plan	25/12/17	25/12/17	27,563 sh4 trades	$82.16avg.	$2,264,503.41	−100.0%
Kymera TherapeuticsKYMR	Open-market sale10b5-1 plan	25/06/03	25/06/03	5,000 sh	$49.04	$245,200	−100.0%
Kymera TherapeuticsKYMR	Open-market sale10b5-1 plan	24/12/02	24/12/02	2,500 sh	$49.00	$122,500	−100.0%
Kymera TherapeuticsKYMR	Open-market sale10b5-1 plan	24/09/17	24/09/17	13,500 sh2 trades	$48.28avg.	$651,775	−100.0%
Replimune GroupREPL	Open-market sale10b5-1 plan	23/09/11–23/09/12	23/09/13	5,658 sh2 trades	$20.01avg.	$113,213.58	−2.1%
Replimune GroupREPL	Open-market sale10b5-1 plan	23/08/22	23/08/24	18,600 sh	$20.01	$372,186	−6.6%
Replimune GroupREPL	Open-market sale10b5-1 plan	23/08/11	23/08/15	1,400 sh	$20.00	$28,000	−0.5%
Replimune GroupREPL	Open-market sale10b5-1 plan	23/07/10	23/07/11	20,000 sh2 trades	$21.58avg.	$431,540.73	−7.1%
Replimune GroupREPL	Open-market sale	23/05/16	23/05/18	5,966 sh	$18.05	$107,686.3	−2.2%